Sensei Biotherapeutics (NASDAQ: SNSE) has finalized its acquisition of Faeth Therapeutics, a clinical-stage company, during a recent webcast and conference call. In tandem with this acquisition, Sensei announced a significant $200 million private placement financing and changes in its leadership and board.
Chris Gerry, President of Sensei, stated that the company began a strategic alternatives process in October 2025 to “maximize shareholder value,” which culminated in the acquisition of Faeth. He emphasized that Faeth is focused on developing “multi-node therapies” that aim to effectively block cancer growth signals across various solid tumor types.
New Leadership and Innovative Approaches
Following the acquisition, Anand Parikh, co-founder and former CEO of Faeth, has joined Sensei as Chief Operating Officer and a board member. Parikh highlighted that Faeth’s approach diverges from conventional oncology methods, which typically concentrate on single genetic mutations. Instead, Faeth’s platform targets “complex multi-node pathways,” employing a multidisciplinary method that includes functional genomics, computational biology, and machine learning.
Parikh also noted the expertise behind Faeth’s founding, mentioning Dr. Lewis Cantley, a key figure in cancer biology and discoverer of the PI3 kinase pathway.
Focus on PIKTOR and Clinical Trials
During the call, Parikh introduced PIKTOR, an investigational oral combination therapy aimed at inhibiting multiple nodes of the PI3K/AKT/mTOR pathway. This therapy combines serabelisib, an alpha-specific PI3K inhibitor, with sapanisertib, an mTORC1/2 inhibitor. Parikh explained that this pathway is one of the most frequently altered oncogenic drivers in solid tumors, and many traditional single-node therapies have faced challenges due to incomplete suppression and dose-limiting toxicities.
The initial focus of PIKTOR includes endometrial, breast, ovarian, and lung cancers, as these areas frequently exhibit PI3K/AKT/mTOR alterations. Currently, PIKTOR is undergoing phase II trials in endometrial cancer, with additional studies planned for breast cancer. Parikh anticipates sharing top-line data from the ongoing phase II trial of PIKTOR combined with paclitaxel in advanced endometrial cancer by the end of 2026. He identified this area as a significant unmet need and a potential first approval opportunity, contingent on supportive data.
Looking ahead, Sensei plans to initiate a phase Ib trial in hormone receptor-positive, HER2-negative advanced breast cancer, a market where the PI3K/AKT/mTOR pathway is well established.
Beyond PIKTOR, the combined entity has a preclinical pipeline that includes an amino acid therapy for rectal cancer and a pediatric program targeting inborn errors of metabolism. The latter involves developing FTX 249 for tyrosinemia type 1 and alkaptonuria, aiming to enhance outcomes and mitigate neurocognitive side effects associated with current treatments.
Transaction Structure and Financing Details
The acquisition was executed as a stock-for-stock merger, where Faeth’s equity interests were exchanged for a combination of Sensei common stock and newly created Series B non-voting convertible preferred stock. This transaction officially closed on February 17, 2026.
In conjunction with the acquisition, Sensei has entered into a securities purchase agreement for a private placement of Series B non-voting convertible preferred stock, expected to yield approximately $200 million in gross proceeds before expenses. This financing is anticipated to close on February 20, 2026.
Participating investors include notable firms such as B Group Capital, Balyasny Asset Management, and Columbia Threadneedle Investments. Each Series B preferred share will be purchased at around $13,850 per share, or approximately $13.85 per share on an as-converted-to-common basis. Upon approval from Sensei’s pre-acquisition shareholders, these preferred shares will convert into common stock.
Gerry noted that no stockholder approval was required for the transaction’s closing under applicable laws, but approval will be sought later in the year for matters including the conversion of the Series B preferred stock into common shares. Following the transactions, ownership is projected to be approximately 4.9% for existing Sensei equity holders, 40.8% for Faeth equity holders, and 54.3% for private placement investors.
The proceeds from the private placement are intended to advance the PIKTOR program toward key clinical readouts, including the phase II trial in endometrial cancer and the planned phase Ib trial in breast cancer. Sensei expects that the total cash available after the private placement, combined with its existing funds, will support the company through several clinical milestones.
About Sensei Biotherapeutics
Sensei Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing immunotherapies that leverage both innate and adaptive immune responses to combat cancer and autoimmune diseases. With proprietary platforms for antibody engineering and biologics, the company aims to produce next-generation checkpoint modulators and immune agonists. Among its leading programs are SIS-100, targeting Siglec-15 for solid tumors, and SIS-101, an antibody directed against CD39 to restore T-cell functionality by modulating adenosine signaling pathways.
